|
|
News Breaks | | | | January 22, 2013 | | 07:38 EDT |  | PGNX | Progenics acquires Molecular Insight Pharmaceuticals in all-stock deal
Progenics Pharmaceuticals announced that it has acquired Molecular Insight Pharmaceuticals, a clinical-stage private biotechnology company with a small molecule chemistry pipeline aimed at enhancing cancer treatment. Under the terms of the all-stock transaction, Progenics exchanged 4,566,210 shares of its common stock, or 8.9% of the total outstanding post-transaction shares, for all of the outstanding shares of Molecular Insight, which will become a wholly-owned subsidiary of Progenics. Molecular Insight has no debt. Progenics may make additional milestone payments to the former owners of Molecular Insight based on future commercial sales of the company's compounds. No royalties are due to the former owners of Molecular Insight. Key elements of Molecular Insight's pipeline include targeted radiotherapy and molecular imaging compounds. | |
|
News For PGNX From The Last 14 Days Check below for free stories on PGNX the last two weeks. |
|
|
| May 10, 2013 | | 09:00 EDT |  | PGNX | Progenics rises 20.9%
Progenics is up 20.9%, or 90c, to $5.20 | | | 07:45 EDT |  | PGNX | Progenics reports Q1 EPS (22c), consensus (19c)
 Subscribe for More Information | |
|
|
|
|
|
|
